A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
M.D. Anderson Cancer Center
Massachusetts General Hospital
OHSU Knight Cancer Institute
Daiichi Sankyo
Boehringer Ingelheim
HealthPartners Institute
Mayo Clinic
Shantou University Medical College
Tempus AI
British Columbia Cancer Agency
Abramson Cancer Center at Penn Medicine
Apollomics Inc.
University of California, Irvine
Azienda USL Reggio Emilia - IRCCS
Tongji Hospital
M.D. Anderson Cancer Center
Elevation Oncology
Teclison Ltd.
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Second Affiliated Hospital of Guangzhou Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zhejiang Provincial People's Hospital
University of Chicago
Weill Medical College of Cornell University
Erasmus Medical Center
N.N. Petrov National Medical Research Center of Oncology
pharmaand GmbH
Northwestern University
Wake Forest University Health Sciences
Kyunghee University Medical Center
MetiMedi Pharmaceuticals
Sun Yat-sen University
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Amgen
Roswell Park Cancer Institute
Roger Williams Medical Center
Novartis
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
Siemens Molecular Imaging